Minipastillas inhibidoras de la proteasa y la fosfatasa Pierce, sin EDTA
Minipastillas inhibidoras de la proteasa y la fosfatasa Pierce, sin EDTA
Thermo Scientific™

Minipastillas inhibidoras de la proteasa y la fosfatasa Pierce, sin EDTA

Las minipastillas inhibidoras de la proteasa y la fosfatasa Thermo Scientific Pierce sin EDTA contienen inhibidores de la proteasa eMás información
Have Questions?
Número de catálogoCantidad
A3296120 pastillas
Número de catálogo A32961
Precio (MXN)
-
Cantidad:
20 pastillas
Las minipastillas inhibidoras de la proteasa y la fosfatasa Thermo Scientific Pierce sin EDTA contienen inhibidores de la proteasa e inhibidores de la fosfatasa para proporcionar una protección completa de amplio espectro frente a la desfosforilación y la degradación proteolítica.

Características de las minipastillas inhibidoras de la proteasa y la fosfatasa sin EDTA:
Fórmula mejorada: Las pastillas se disuelven rápidamente y forman una solución transparente.
Económicas: Son más rentables que otras formulaciones disponibles en el mercado para volúmenes equivalentes.
Prácticas: Están compuestas a partir de formulaciones listas para usar, de amplio espectro y completamente públicas.
Compatibles: Pueden usarse directamente en ensayos Pierce BCA.
Sin EDTA: Estas pastillas están formuladas sin EDTA, un inhibidor de la metaloproteinasa (esto solo aplica a las formulaciones sin EDTA)

Las minipastillas inhibidoras de la proteasa y la fosfatasa Pierce contienen aprotinina, bestatina, E-64 y leupeptina para proporcionar protección contra la degradación por las proteasas de serina, las proteasas de cisteína y las proteasas de ácido aspártico. Para evitar la actividad de desfosforilación de las serina/treonina y tirosina fosfatasas, cada pastilla también contiene fluoruro sódico, ortovanadato sódico, pirofosfato sódico y beta-glicerofosfato. Las pastillas inhibidoras de la proteasa y la fosfatasa Pierce son estables a 4 °C durante un máximo de 12 meses, y cada comprimido es suficiente para 10 ml de solución.

Las minipastillas inhibidoras de la proteasa y la fosfatasa Pierce son las primeras pastillas inhibidoras completas. Añadir un comprimido a 10 ml de tampón de lisis proporciona una protección completa contra la actividad de la proteasa y la fosfatasa durante la extracción de proteínas y la purificación de proteínas. Hay dos formulaciones de este inhibidor disponibles, una que contiene EDTA y otra sin. Aunque ambas formulaciones tienen inhibidores de metaloproteasa, una formulación libre de EDTA está disponible para aplicaciones que requieren cationes divalentes para la actividad proteica. Del mismo modo, la EDTA y ciertos inhibidores de la fosfatasa interfieren con la cromatografía de afinidad a quelatos metálicos inmovilizados (IMAC) y la electroforesis 2D. Dialice o desalte la muestra antes de realizar estos procedimientos. La formulación del inhibidor de la proteasa y la fosfatasa es compatible con la espectrometría de masas, ya que no contiene AEBSF.

Productos relacionados
Minipastillas inhibidoras de la fosfatasa Pierce
Minipastillas inhibidoras de la proteasa Pierce sin EDTA

Para uso exclusivo en investigación. No apto para uso en procedimientos diagnósticos.
Especificaciones
InhibidoresInhibidor de la proteasa, inhibidor de la fosfatasa
Cantidad20 pastillas
Condiciones de envíoHielo húmedo
Suficiente paraSolución de 10 ml
FormularioSólido
Línea de productosPierce
Tipo de productoInhibidor
Unit SizeEach
Contenido y almacenamiento
1 vial, almacenar entre 2 °C y 8 °C

Preguntas frecuentes

Can I use just part of the Pierce Protease Inhibitor XL Capsules, EDTA-Free and save part of the capsule for later use?

We do not recommend “splitting” the capsule into smaller portions. Researchers using less than 500 mL should choose a different format (liquid or tablet) of protease inhibitors.

Find additional tips, troubleshooting help, and resources within our Protein Purification and Isolation Support Center.

What formats of protease inhibitors do you offer?

We offer standalone protease inhibitors (AEBSF, Aprotinin, PMSF, EDTA, etc.), as well as cocktails or combinations of protease inhibitors in liquid, tablet, and larger capsule formats. These cocktails of protease inhibitors can also be purchased in combination with a cocktail of phosphatase inhibitors, in both liquid and tablet form, for even greater convenience.

Find additional tips, troubleshooting help, and resources within our Protein Purification and Isolation Support Center.

Do you offer any of the components of the Pierce protease, phosphatase and (protease and phosphatase) inhibitor tablets and mini tablets individually?

Yes, the following components of the Pierce protease, phosphatase and (protease and phosphatase) inhibitor tablets and mini tablets are offered separately:

- AEBSF (Cat. No. 78431)
- Aprotinin (Cat. No. 78432)
- Bestatin (Cat. No. 8433)
- E-64 (Cat. No. 78434)
- Leupeptin (Cat. No. 78435)
- Pepstatin A (Cat. No. 78436)
- EDTA (Cat. No. 17892).

Find additional tips, troubleshooting help, and resources within our Protein Purification and Isolation Support Center.

What are the concentrations of the various components of the protease and phosphatase inhibitor tablets and mini tablets?

The final concentration of each component in the protease and phosphatase inhibitor tablets and mini tablets is proprietary. We release only the identities of the inhibitors.

Find additional tips, troubleshooting help, and resources within our Protein Purification and Isolation Support Center.

Can I store the reconstituted solution of protease, phosphatase and (protease and phosphatase) inhibitor tablet or mini tablet and if so, for how long?

The Pierce protease, phosphatase, as well as (protease and phosphatase) inhibitor tablets and mini tablets are stable for at least one year when stored at 4 degrees C, but we only recommend preparing fresh solutions just before needed. If you are interested in liquid protease or phosphatase inhibitors, please use our inhibitor cocktails (https://www.thermofisher.com/search/results?query=protease%20inhibitor%20cocktails&focusarea=Search%20All).

Find additional tips, troubleshooting help, and resources within our Protein Purification and Isolation Support Center.

Citations & References (4)

Citations & References
Abstract
Hypoxia is linked to acquired resistance to immune checkpoint inhibitors in lung cancer.
Authors:Robles-Oteíza C,Hastings K,Choi J,Sirois I,Ravi A,Expósito F,de Miguel F,Knight JR,López-Giráldez F,Choi H,Socci ND,Merghoub T,Awad M,Getz G,Gainor J,Hellmann MD,Caron É,Kaech SM,Politi K
Journal:The Journal of experimental medicine
PubMed ID:39585348
Despite the established use of immune checkpoint inhibitors (ICIs) to treat non-small cell lung cancer (NSCLC), only a subset of patients benefit from treatment and ∼50% of patients whose tumors respond eventually develop acquired resistance (AR). To identify novel drivers of AR, we generated murine Msh2 knock-out (KO) lung tumors ... More
Bioorthogonal Conjugation-Assisted Purification Method for Profiling Cell Surface Proteome.
Authors:Liu G,Choi MH,Ma H,Guo X,Lo PC,Kim J,Zhang L
Journal:Analytical chemistry
PubMed ID:35019258
Surface biotinylation has been widely adapted in profiling the cellular proteome associated with the plasma membrane. However, the workflow is subject to interference from the cytoplasmic biotin-associated proteins that compete for streptavidin-binding during purification. Here we established a bioorthogonal conjugation-assisted purification (BCAP) workflow that utilizes the Staudinger chemoselective ligation to ... More
Hypoxia is linked to acquired resistance to immune checkpoint inhibitors in lung cancer
Authors:Robles-Oteíza C, Hastings K, Choi J, Sirois I, Ravi A, Expósito F, de Miguel F, Knight JR, López-Giráldez F, Choi H, Socci ND, Merghoub T, Awad M, Getz G, Gainor J, Hellmann MD, Caron É, Kaech SM, Politi K.
Journal:J Exp Med
PubMed ID:39585348
Despite the established use of immune checkpoint inhibitors (ICIs) to treat non-small cell lung cancer (NSCLC), only a subset of patients benefit from treatment and ∼50% of patients whose tumors respond eventually develop acquired resistance (AR). To identify novel drivers of AR, we generated murine Msh2 knock-out (KO) lung tumors ... More
Mitochondria dysregulation contributes to secondary neurodegeneration progression post-contusion injury in human 3D in vitro triculture brain tissue model.
Authors:Liaudanskaya V,Fiore NJ,Zhang Y,Milton Y,Kelly MF,Coe M,Barreiro A,Rose VK,Shapiro MR,Mullis AS,Shevzov-Zebrun A,Blurton-Jones M,Whalen MJ,Symes AJ,Georgakoudi I,Nieland TJF,Kaplan DL
Journal:Cell death & disease
PubMed ID:37537168
Traumatic Brain injury-induced disturbances in mitochondrial fission-and-fusion dynamics have been linked to the onset and propagation of neuroinflammation and neurodegeneration. However, cell-type-specific contributions and crosstalk between neurons, microglia, and astrocytes in mitochondria-driven neurodegeneration after brain injury remain undefined. We developed a human three-dimensional in vitro triculture tissue model of a ... More